Telix Pharmaceuticals Ltd represents a strong commitment to improving the diagnosis and treatment of cancer. With a focus on molecularly targeted radiation therapy, the company aims to develop innovative radiopharmaceuticals that can deliver more precise and effective cancer treatments. Telix Pharmaceuticals embraces a patient-centered approach, continually striving to enhance patient outcomes and improve quality of life. The company is dedicated to fostering collaborations, driving scientific advancements, and delivering transformative therapies to individuals battling cancer. Telix Pharmaceuticals Ltd stands as a beacon of innovation, aiming to revolutionize the field of cancer medicine with its cutting-edge technologies and unwavering dedication to making a difference.

Telix Pharmaceuticals Ltd primarily operates in several countries and regions, including Australia, the United States, Europe, and Japan.

Telix Pharmaceuticals Ltd has achieved several significant milestones. Firstly, the company successfully completed its Phase III clinical trial for TLX591-CDx, a prostate cancer imaging agent. Additionally, Telix Pharmaceuticals received regulatory approval in the United States, Europe, and Canada for TLX591-CDx, allowing for its commercialization. Another notable achievement is the successful completion of a collaboration agreement with China Grand Pharma, expanding Telix's presence in the Chinese market. Furthermore, Telix Pharmaceuticals entered into a licensing agreement with ANMI SA, enhancing its product portfolio for molecular imaging. These achievements highlight Telix Pharmaceuticals' commitment to developing innovative solutions in the field of radiopharmaceuticals.

Telix Pharmaceuticals Ltd is an innovative biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for cancer diagnosis and treatment. Established in 2016, Telix has rapidly grown into a global player in the molecularly targeted radiation therapy field. The company has successfully acquired and developed a diverse portfolio of diagnostic and therapeutic products, leveraging its cutting-edge technology and strategic partnerships. Telix has made significant progress in clinical trials, regulatory approvals, and commercialization efforts, demonstrating its commitment to improving patient outcomes in oncology. With its dedicated team and robust pipeline, Telix Pharmaceuticals Ltd is poised to revolutionize cancer management through personalized and targeted radiopharmaceuticals.

The main competitors of Telix Pharmaceuticals Ltd in the market are other pharmaceutical companies operating in the same sector, focusing on molecularly targeted radiation (MTR) therapies and diagnostic imaging products for oncology. These competitors include established players such as Advanced Accelerator Applications SA (a Novartis company), Bayer AG, Curium Pharmaceuticals, and Progenics Pharmaceuticals. Telix Pharmaceuticals Ltd distinguishes itself through its innovative radiopharmaceutical solutions, strategic collaborations, and ongoing clinical trials.

Telix Pharmaceuticals Ltd is primarily active in the pharmaceutical and biotechnology industries.

The business model of Telix Pharmaceuticals Ltd revolves around the development and commercialization of molecularly targeted radiation (MTR) products. As a leading biopharmaceutical company, Telix focuses on producing innovative diagnostic and therapeutic solutions for patients suffering from cancer. By utilizing its expertise in radiopharmaceuticals and molecular targeting, Telix aims to enhance the precision and efficacy of cancer diagnosis, imaging, and treatment. Through collaborations with various partners, Telix strives to bring advanced diagnostic imaging technologies and personalized treatment options to healthcare professionals and patients worldwide. Telix Pharmaceuticals Ltd plays a crucial role in improving patient outcomes and advancing the field of nuclear medicine.

لا يمكن حساب مضاعف الربحية للسهم لـTelix Pharmaceuticals في الوقت الحالي.

لا يمكن حالياً حساب معامل القيمة السوقية إلى العائدات لـ Telix Pharmaceuticals.

نقاط جودة AlleAktien لـ Telix Pharmaceuticals هي 3/10.

المتوقعة Telix Pharmaceuticals الإيرادات هي ١٫٢٩ مليارات AUD.

صافي الربح المتوقعة Telix Pharmaceuticals هو ١٨٦٫٧٢ مليون. AUD.

Telix Pharmaceuticals Ltd is an Australian biotechnology company specializing in the development and commercialization of diagnostic technologies and therapeutic products for oncology.

يوزع Telix Pharmaceuticals أرباحًا قدرها 0 AUD من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ Telix Pharmaceuticals في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـTelix Pharmaceuticals هو AU000000TLX2.

رمز WKN لـ Telix Pharmaceuticals هو A2H7JK.

الرمز المُختصر لـ Telix Pharmaceuticals هو TLX.AX.

خلال آخر 12 شهراً، دفعت Telix Pharmaceuticals توزيعات أرباح بقيمة . وهذا يعادل عائد توزيعات أرباح يقارب . ومن المتوقع أن تدفع Telix Pharmaceuticals خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ0 AUD.

نسبة توزيعات الأرباح الحالية لـ Telix Pharmaceuticals هي .

Telix Pharmaceuticals يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر .

Telix Pharmaceuticals دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة 0 AUD. وهذا يعادل عائد توزيعات أرباح قدره 0 %.

Telix Pharmaceuticals يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة 0 AUD من Telix Pharmaceuticals المُعلن عنها في ٢٥‏/٧‏/٢٠٢٥، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ٢٥‏/٧‏/٢٠٢٥.

تم توزيع آخر دفعة من الأرباح بتاريخ ٢٥‏/٧‏/٢٠٢٥.

في العام 2024، وزعت Telix Pharmaceuticals 0 AUD كأرباح أسهم.

يتم توزيع أرباح Telix Pharmaceuticals بالعملة AUD.